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Abstract
Aggressive clinical and public health interventions have resulted in significant reduction in coronary artery disease
(CAD) worldwide. However, South Asian immigrants (SAIs) exhibit the higher prevalence of CAD and its risk factors
as compared with other ethnic populations. The objective of the current study is to assess the prevalence of
metabolic syndrome (MS), its association with high density Lipoprotein (HDL) function, Apo lipoprotein A-I (APOA1)
gene polymorphisms, and sub-clinical CAD using common carotid intima-media thickness (CCA-IMT) as a surrogate
marker. A community-based cross-sectional study was conducted on SAIs aged 35-65 years. Dysfunctional/pro-
inflammatory (Dys-HDL) was determined using novel cell free assay and HDL inflammatory index. Six intronic
APOA1 gene polymorphisms were analyzed by DNA sequencing. According to the International Diabetes
Federation definition, MS prevalence was 29.7% in SAIs without CAD and 26% had HDL inflammatory index ≥ 1
suggesting pro-inflammatory Dys-HDL. Six novel APOA1 single nucleotide polymorphisms (SNPs) were analyzed
with logistic regression, three SNPs (G2, G3, and G5) were found to be significantly associated with MS (p = 0.039,
p = 0.038, p = 0.054). On multi-variate analysis, MS was significantly associated with BMI > 23 (P = 0.005), Apo-A-I
levels (p = 0.01), and Lp [a] (p < 0.0001). SAIs are known to be at a disproportionately high risk for CAD that may
be attributed to a high burden for MS. There is need to explore and understand non-traditional risk factors with
special focus on Dys-HDL, knowing that SAIs have low HDL levels. Large prospective studies are needed to further
strengthen current study results.
Introduction
Despite improvements in clinical outcomes and decrease
in event rates by 50% over the past 30 years, coronary
a r t e r yd i s e a s e( C A D )c o n t i n u e st ob eam a j o rc a u s eo f
death in the US [1]. A disturbing trend toward high rates
of CAD, insulin resistance or metabolic syndrome (MS)
has been noted among South Asian immigrants (SAIs)-
people from the Indian sub-continent (Bangladesh,
Pakistan, India, Sri Lanka, Nepal and Bhutan) [2-6]. This
is particularly alarming for several reasons; (i)S o u t h
Asians represent one-fifth of the global population. In the
US, 3.6 million, or 1.3% of the population, is made up of
SAIs [7-10]. SAIs are the fastest growing Asian immi-
grant population in the US which has more than doubled
since the 1980 s (growth rate of 108%), and of that
growth, three-fourths is due to immigration [7] and
(ii) prevalence of CAD in SAIs is twice as high as other
immigrant populations [11] and three times higher than
in the Framingham Heart Study (FHS), even after adjust-
ment for all conventional risk factors [12-14].
MS plays a causative role in the prevalence of type II
diabetes (T2D) as well as premature atherosclerosis in
SAIs, a pattern increasingly noted in parallel with migra-
tion and urbanization. Current guidelines for the criteria
used to define MS including body mass index (BMI)
and waist circumference (WC), were predominantly
modeled after white Caucasians and are likely to under-
estimate MS and abdominal obesity in SAIs [13-16]. Evi-
dence suggests that immigration from South Asia to the
US, and the acculturation that occurs, exacerbates the
consequences of MS and increases CAD risk. Moreover,
low HDL is one of the components of MS and SAIs are
known to have low HDL. However, assessment of HDL
functionality and its correlation with MS is important
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understand the type of MS and its association with dys-
functional HDL-Dys-HDL (if present), we conducted a
National Institutes of Health (NIH) funded project with
an objective to assess the prevalence of MS, its associa-
tion with CAD and HDL functionality in SAIs. We also
assessed Apo lipoprotein A-I (APOA1) gene polymorph-
isms to understand their association with MS and other
factors including Dys-HDL and low HDL.
Apo A-I (APOA1 gene; Apo A-I protein) is the major
protein component of HDL and consists of 243 amino
acids, synthesized mainly in the liver and to some extent
in the small intestine [17]. The inverse relationship
between HDL plasma levels and CAD has been attribu-
ted to the role of HDL and its major constituent Apo A
and reverse cholesterol transport (RCT). The efficiency
of RCT depends on the specific ability of ApoA- Ito
promote cellular cholesterol efflux, bind lipids, activate
lecithin: cholesterol acyltransferase (LCAT), and form
mature HDL that interacts with specific receptors and
lipid transfer proteins[18]. The APOA1 gene is present
along with APOC3, APOA4 and APOA5 genes and
located on chromosome 11 (11q23.3-qter) [19]. This
gene cluster region containsa tl e a s t1 8 2d i s t i n c tS N P s ,
making it a relatively heterogeneous genetic region [20].
A recent study of SAIs revealed a prevalence of 6 novel
SNPs in the intronic regions of the APOA1 gene, one of
which (G5: C938T) was significantly associated with low
plasma HDL levels [19]. South Asians are commonly
known to have low HDL levels and we have shown an
association of Apo A-I with low HDL in SAIs [19]. An
additional SNP (G-75A) identified in the APOA1 gene is
located in the 5’ untranslated region [20] and is present
in 11-35% of the population, with frequency variation
depending on ethnicity or geographic origin of the study
population [20-22]. We predict that specific APOA1
gene polymorphisms may be related to increased MS
risk, and therefore increased CAD risk.
Several groups have developed criteria for diagnosing
MS; for example, World Health Organization (WHO),
National Cholesterol Educational Program ATP III
(NCEP ATP III), and International Diabetes Federation
(IDF) have proposed different criteria for MS diagnosis
(Table 1). Of these, only the IDF considers ethnicity in
their criteria [14-16]. Though we present MS prevalence
based on all three criteria, we used the IDF guidelines
(Appendix 1) for all data analysis in the current study
[15,16]. According to the IDF classification, MS is
defined as the presence of three or more of the follow-
ing: 1) increased waist circumference (≥ 90 cm in males,
≥ 80 cm in females), this is an essential component; 2)
elevated serum triglycerides (≥150 mg/dl); 3) low HDL
cholesterol (< 40 mg/dl in males, <50 mg/dl in females);
4) hypertension (systolic blood pressure ≥130 mmHg
and/or diastolic blood pressure ≥85 mmHg) or medical
treatment of previously diagnosed hypertension; and 5)
elevated fasting glucose levels (≥110 mg/dl). In addition,
since lower cut-off values of body mass index (BMI)
have been suggested for South Asians (BMI ≥ 23 is con-
sidered abnormal), we have used these values for the
current study [23].
Study Design and Methods
Using an epidemiologic cross-sectional study design,
SAIs between the ages of 35-65 years without a known
history of CAD were randomly recruited from the South
and Midwest regions of the US (States of Georgia,
Kansas and Missouri). We chose this age range because
CAD and its risk factors occur at younger ages in SAIs
as compared to other populations [3]. The SAI popula-
tion in the US is most readily accessed through their
temples of worship. Therefore, although study informa-
tion was made available and distributed using different
methods, the majority of study subject recruitment was
done through Hindu temples. This approach was used
as no national level census or data are available on
South Asians providing a correct estimate of total popu-
lation. Therefore, we understand that results of this
study may not be generalizable; however, most SAIs
Table 1 Socio-Demographics of Study Group (n = 129)
Variable n (%)
Age (years) 51.30 ± 9.23 *
Male 51.04 ± 9.64*
Female 51.68 ± 8.70*
Gender
Male 76 (58.6)
Female 53 (41.4)
Ethnicity
South Indian 33 (25.6)
Guajarati 23 (17.8)
Hindi 23 (17.8)
Bengali 10 (7.8)
Punjabi 8 (6.2)
Other 4 (3.2)
Work Type
Employee full time 91 (70.5)
Homework 14 (10.9)
Employee part time 9 (7.0)
Unemployed 6 (4.7)
Other 8 (6.2)
Education
Post-Graduate 67 (51.9)
Graduate 30 (23.3)
Undergraduate 24 (18.6)
Other 1 (0.8)
*Mean ± SD (Standard Deviation).
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groups. Study information was made available by distri-
buting flyers in the temples and announcements
through local newspapers outlining the purpose, ratio-
nale, and design of the study. After the written informed
consent was obtained, information on socio-demo-
graphic status, ethnicity (based on spoken language),
personal lifestyle characteristics, and both traditional
and non-traditional risk factors for CAD were obtained.
Twelve-hour fasting blood samples were collected for
measurements of high sensitivity C-reactive protein
(hsCRP), total lipid testing including total cholesterol,
Triglycerides (TGs), high density lipoprotein (HDL), low
density lipoprotein (LDL), and lipoprotein a (Lp[a]).
Insulin, Fibrinogen, Homocysteine and Apo A-I serum
levels were also measured.
Carotid Ultrasound Doppler for Common Carotid Intima-
Media Thickness (CCA-IMT)
CCA-IMT is defined by Pingoli and colleagues as the
distance from the leading edge of the lumen-intima
interface of the far wall to the leading edge of the media
-adventitia interface of the far wall [24]. B-mode ultra-
sound scanning of bilateral CCAs was performed by a
trained non-invasive vascular ultrasound technician at
the University of Kansas Medical center study clinics,
using SonoSite MicroMaxx™ ultrasound machine
(SonoSite, Inc Bothell, WA) with a 10.0 MHz linear
array transducer. Both CCAs were scanned in supine
position. A total of eight images were obtained (four on
each side), 1 cm proximal to the carotid bulb using a
posterior wall (far wall) approach. ECG leads were
placed to obtain end-diastolic measurements. Images
were recorded and stored on a disk. The CCA-IMT
approach for IMT measurements was preferred because
the CCA-IMT is reproducible and predictive of future
cardiovascular events, and data collection is more com-
plete than the use of other non-invasive markers
[25,26]. Measurements of the internal carotid and bifur-
cation segments tend to have many more missing
values. The Mannheim Intima-Media Thickness Con-
sensus suggested that measurement of the CCA is ideal
[25].
Any focal thickening of the intima-media complex or
carotid plaque was not included in the analysis. Two
cardiologists, who were blinded to participants’ identities
and clinical information, analyzed stored images by
using the SonoCalc™ IMT software. Measurement of
the far wall of the carotid artery was preferred, since
studies comparing ultrasound measurements with histol-
ogy suggest that far-wall CCA-IMT measurements are
more indicative of the true thickness of the arterial wall
[26,27]. Near-wall CCA measurements, in comparison,
are limited by their dependence on the axial resolution,
gain settings of the equipme n tu s e da n di na d d i t i o n ,
show greater variation between repeated measurements
[25]. Participants with values equal to or greater than
0.80 mm were considered to be IMT positive. Previous
epidemiological studies suggest that a value of IMT at
or above 0.80 mm is associated with a significantly
increased absolute risk of CAD [26]. In this study CCA-
IMT values of 0.80 mm or more were considered abnor-
mal. CCA-IMT values were adjusted for age as age can
influence IMT [25,26]. We did not include plaque read-
ings in this study.
Assessment of Dysfunctional HDL (Dys-HDL)
The diagnosis of Dys-HDL has historically been made
with a cell-based assay that requires endothelial cells,
smooth muscle cells, and monocytes. However, the use
of a cell-based assay is not practical for large-scale stu-
dies. A cell-free assay has been developed to detect
HDL that is dysfunctional [28]. The details on Dys-HDL
assessment using the cell-free assay have been published
previously [28,29]. Briefly, this is a rapid test for HDL
function that does not require cells and gives results
highly comparable to those of the previously described
cell-based assay. HDL was isolated from blood samples
using dextran sulphate precipitation.LDL, necessary in
the cell-free assay for testing the ability of HDL to pro-
tect against LDL oxidation, was prepared from a normal
donor, aliquoted and then cryo-preserved in sucrose.
Dichlorofluorescein-diacetate (DCFH-DA) was dissolved
in fresh methanol at 2.0 mg/ml, incubated at room tem-
perature, and protected from light for 30 min, which
resulted in the release of dichlorofluorescein (DCFH)
producing an intense fluorescence upon interaction with
oxidized lipid. Fluorescence was determined using a
plate reader (Spectra Max, Gemini XS; Molecular
Devices) at an excitation wavelength of 485 nm, an
emission wavelength of 530 nm, and a cutoff of 515 nm
with the photomultiplier sensitivity set at medium. For
this study, the coefficient of variation for this assay was
9.6% [28]. Similarly, the HDL-inflammatory index (HII)
was calculated by normalizing the cell-free assay values
obtained for LDL alone as 1.0 [29]. If the addition of a
test HDL resulted in a value of 1.0 or greater, the test
HDL was classified as pro-inflammatory (dysfunctional).
Conversely, if the addition of the standard normal LDL
together with a test HDL resulted in a value less than
1.0, the test HDL was classified as anti-inflammatory.
To support the results of the cell free assay, we also
measured serum hsCRP.
DNA Extraction From Blood Specimens
Each blood sample was assigned a unique DNA identifi-
cation code. Genomic DNA was extracted from whole
blood (2 mls) using the Qiagen DNA Isolation Kit (Qia-
gen
®, Valencia, CA, USA), according to the manufac-
turer’s protocol, which yields 4-12 μg of high quality
Dodani et al. Lipids in Health and Disease 2011, 10:45
http://www.lipidworld.com/content/10/1/45
Page 3 of 10DNA. An aliquot of DNA was diluted and the absor-
bance at l 260 nm and l 280 nm measured using an
Eppendorf Biophotometer for verification of quality and
concentration. DNA samples were diluted to 50 ng/μl
and stored at -20°C.
DNA Sequencing of APOA1 Gene
PCR amplification was performed on genomic DNA to
a m p l i f ya1 6 8 3b pf r a g m e n to ft h eAPOA1 gene encom-
passing the SNPs to be analyzed using forward 5’
CACAATGGACAATGGCAACT 3’ and reverse 5’ CCA-
GATCCTTGCTCATCTCC 3’ PCR primers. The PCR
fragment was purified using the QIAquick PCR purifica-
tion kit (Qiagen, Valencia, CA). Sequencing was per-
formed commercially by ACGT Inc. (Wheeling, IL) using
a series of two sequencing primers on the forward strand
(first sequencing primer: 5’ CTTGACCCCTGCCCTG-
CAGC 3’; second sequencing primer: 5’ CGGCAGAGA-
CTATGTGTCCCAG 3’) which completely encompassed
the six SNPs within a range of high fidelity sequencing
(< 600 bp). Sequencing data for each subject were
provided in the form of raw electropherogram files
from which DNA sequences were derived using Ridom
Trace Edit software (Ridom Bioinformatics, Würzburg,
Germany). All SNPs were determined and verified both
from the derived DNA sequence and visual inspection of
the electropherogram. Results were analyzed by com-
parative NCBI BLAST sequence analysis. The reference
sequence used was NCBI RefSeq NC_000011.9, derived
from the Genome Reference Consortium Human Build
37 (GRCh37), Primary Assembly http://www.ncbi.nlm.
nih.gov/gene.
Power Calculations and Statistical Analysis
We enrolled 148 first generation SAIs with different eth-
n i cb a c k g r o u n d s .T h i si sap i l o ts t u d ys u r v e yw i t ha
fixed sample of 129 to assess the MS and CAD risk fac-
tor profile in SAIs. The power calculation for assessing
dysfunctional HDL were based on a chi-square contin-
gency table analysis [Dys- HDL (Yes/No) vs. MS (Yes/
No)], from available data on MS in South Asians [22].
Assuming that 15% of the 129 subjects have MS using
IDF criteria and 5% among non-MS, we have a 91%
power at 5% alpha level and 85% power at 1% alpha
level to detect the Dys-HDL difference in two groups.
Baseline socio-demographic characteristics and CAD
risk factors were summarized by frequency distributions
and percentages for qualitative measures and means and
standard deviations for quantitative measures. Figures
were presented in percent estimates. Maximum likeli-
hood estimates and asymptotic 95% confidence intervals
were calculated for the prevalence of disease/diagnosis
outcome measures. Bivariate tests of association and
odds ratios were performed by the Fisher Exact Test
methods with age and gender adjustment where
necessary. Genetic analysis of APO A1 were analyzed
using logic regression methods. All statistical tests were
two-sided and performed at the 0.05 level of significance.
Results
Of the total sample of 148 subjects, complete informa-
tion was obtained on 129 subjects, constituting our
study sample (Table 1). The mean age of subjects was
51 ± 9.23 years with almost an equal number of males
and females (Table 1). The study group presented a
homogenous mixture of various ethnicities including
Hindi speaking (18%), Gujratis (18%), and South Indians
(26%). More than 50% received up to post-graduate
level education. CAD risk factors prevalence (Table 2)
was (a)h y p e r t e n s i o n - 4 5 %( b) high cholesterol ≥ 200
mg/dl -41.6%, (c) HDL < 40 mg/dl-26.4% (d) LDL ≥ 150
mg/dl-16.9%, (e) Lp[a]-35.7% (f)h s C R P( ≥ 5)-48.7%, (g)
BMI ≥ 23-78.4% (h) obesity (BMI ≥ 30)-18.2%; (i) family
history of CAD and T2 D was 34.4% and 48.4%, respec-
tively. Eighty-three percent of our subjects were physi-
cally active. Sub-clinical CAD using CCA-IMT ≥ 0.8
mm (as a surrogate marker) was seen in 38.5% of sub-
jects. Increased obesity is also reflected by an increased
waist circumferences in both genders in this study
(Table 3).
MS Prevalence and Associations with Risk Factors
Based on the IDF definition, MS was seen in 29.7% of
SAIs without CAD. Whereas according to WHO and
NCEP ATP III criteria, the prevalence of MS was 13.3%
and 40%, respectively, indicating under- and over-
estimation of MS prevalence by WHO and NCEP ATP
III criteria, respectively (Table 2). On multi-variate ana-
lysis using Fisher Exact test, MS was significantly asso-
ciated with BMI > 23 (p < 0.005), Apo-A-I levels (p <
0.01), and Lp[a] (p < 0.0001) (Table 4, Figure 1).
Dys-HDL, Low HDL and APOA1 Gene Polymorphisms
Dys-HDL was measured by HDL inflammatory index
using a novel cell free assay [28]. Twenty-six percent of
our subjects had an HDL inflammatory index ≥ 1s u g -
gesting pro-inflammatory HDL (Dys-HDL). Six APOA1
single nucleotide polymorphisms (SNPs) (Table 5) were
analyzed discovered in the SAI in this study. These
APOA1 polymorphisms were also observed in previous
studies [19]. On logistic regression analysis, three of the
six SNPs (G2, G3, and G5) were found to be signifi-
cantly associated with MS and may be related to high
MS prevalence in SAIs. On the Fisher Exact test analy-
sis, the association of MS with Dys-HDL (p = 0.0348)
and CCA-IMT (p = 0.0024) was statistically significant
even after age and gender adjustment (Table 6). The
odds ratio with 95% confidence interval of CAD risk fac-
tors and APOA1 SNPs with MS are shown in Figure 1.
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It is predicted that more than one-half the world’s CVD
burden will be borne by the people from the Indian sub-
continent in the next decade [30]. There is evidence to
suggest that the presence of MS predicts the future risk
for T2 D and CAD. MS is a common and complex dis-
order combining obesity, dyslipidemia, hypertension,
and insulin resistance. It is a primary risk factor for T2
D and CVD. In this study, we showed for the first time
that MS is associated with Apo-A-I levels as well as
APOA1 gene polymorphisms. This may relate to low
HDL and/or Dys-HDL in SAIs predisposing them to
increased future risk of CAD. However, larger studies
are required to confirm these findings. Interestingly, the
conventional descriptions of MS have no mention of
genetic factors serving as CAD risk markers.
The most accepted and unifying hypothesis to
describe the patho-physiology of the MS is insulin resis-
tance. Our study also supports that SAIs have high T2
Dp r e v a l e n c er a t e sd e s p i t el o wb o d yw e i g h t( i . e .1 7 %i n
Table 3 Prevalence of Metabolic Syndrome (MS)
n%
MS by IDF NO 68 53.1
YES 38 29.7
MS by NCEP NO 76 59.4
YES 52 40.6
MS by EUROPEAN GROUP NO 96 75.0
YES 32 25.0
MS by WHO NO 111 86.7
YES 17 13.3
European group = European Group for the Study of Insulin Resistance;
IDF = International Diabetes Federation;
NCEP ATP III = National Cholesterol Education Program Adult Treatment Panel.
Table 2 CAD Risk Factors and Other Markers in Study
Group (n = 129)
Variables n (%) Mean ± SD
BMI 26.37 ± 5.08
Normal (< 23) 27(21.62) 21.84 ± 1.68
Overweight (23 - 30) 76(60.14) 25.82 ± 2.05
Obese (≥ 30) 22 (18.24) 34.07 ± 6.45
Total LDL 117.63 ± 35.61
Normal (< 150 mg/dl) 103(83.06) 106.08 ± 24.73
Abnormal (≥ 150 mg/dl) 21(16.94) 174.95 ± 24.44
Total HDL 48.38 ± 10.99
Normal (> 40 mg/dl) 92(73.6) 52.95 ± 8.98
Abnormal (≤ 40 mg/dl) 33(26.4) 35.79 ± 4.31
HDL2
¥ 12.03 ± 3.69
Normal (≥10 mg/dl) 26(34.67) 8.19 ± 1.81
Abnormal (< 10 mg/dl) 49(65.33) 14.12 ± 2.63
HDL3
% 35.91 ±8.25
Normal (≥30 mg/dl) 18(24.0) 26.11 ± 3.34
Abnormal (< 30 mg/dl) 57(76.0) 39.02 ± 6.86
Dys-HDL* 0.83 ± 0.74
Normal (< 1.0) 88(73.95) 0.53 ± 0.17
Dysfunctional (≥ 1.0) 31(26.05) 1.71 ± 1.02
Total
Cholesterol
193.17 ± 38.97
Normal (< 200 mg/dl) 73(58.4) 167.74 ± 22.34
Abnormal (≥ 200 mg/dl) 52(41.6) 229.31 ± 27.37
Triglycerides 160.44 ± 114.56
Normal (< 150 mg/dl) 73(58.4) 99.23 ± 26.88
Abnormal (≥ 150 mg/dl) 52(41.6) 246.90 ± 134.70
Lipoprotein
[a]
13.61 ± 18.99
Normal (< 10 mg/dl) 79(64.23) 4.59 ± 1.79
Abnormal (≥10 mg/dl) 44(35.77) 30.02 ± 24.46
Apo
lipoprotein
A-I
150.36 ± 31.94
Normal (94 - 176 mg/dl) 95(76.0) 142.06 ± 22.19
Abnormal (else) 30(24.0) 178.13 ± 41.30
hsCRP** 3.32 ± 2.56
Normal (< 5 mg/L) 63(51.22) 1.24 ± 1.09
Abnormal (≥ 5 mg/L) 60(48.78) 5.55 ± 1.60
Homocysteine 10.34 ± 7.71
Normal (< 12 umol/L) 74(77.89) 7.96 ± 2.06
Abnormal (≥ 12 umol/L) 21(22.11) 18.79 ± 13.08
CCA-IMT 0.73 ± 0.17
Normal (< 0.8 mm) 48(61.54) 0.649 ± 0.094
Abnormal (≥ 0.8 mm) 30(38.46) 0.916 ± 0.15
Waist Circumference (cm) 93.72 ±14.08
Male 61 (48.66) 95.53 ± 12.74
Female 46 (27.98) 91.47 ± 15.58
Physical
Activity
No 20 (15.50)
Yes 109 (84.50)
Smoking No 121 (93.80)
Yes 8 (6.20)
Table 2 CAD Risk Factors and Other Markers in Study
Group (n = 129) (Continued)
Type II
Diabetes
#
No 89 (69.53)
Yes 39 (30.47)
High Blood
Pressure
#
No 70 (54.69)
Yes 58 (45.31)
Family
history of
T2D
$
No 48 (43.24)
Yes 63 (56.76)
Family
history of
CAD
$
No 67 (60.36)
Yes 44 (39.64)
*Dys-HDL = Dysfunctional HDL measure by HDL Inflammatory index; **hsCRP
= High sensitivity C reactive protein;
#History/examination and/or blood test;
$T2D = Type II diabetes; CAD = Coronary Artery Disease.
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SAIs have a smaller body habitus. Obesity, by its classic
definition, is rare among SAIs [11,15,16] as seen in this
study, as well. However, the peculiar body habitus and
in particular, the unique pattern of fat distribution, are
critically significant risk factors described specifically for
SAIs. Moreover, SAIs have a higher visceral fat mass
than persons of other ethnicities with comparable BMI
[4-7,15,27]. The fat distribution is focused in the
abdominal visceral space, and this peculiarity is seen in
subjects of normal or even subnormal body weight. Our
study findings also support the fact that though BMI was
not significantly high in this group, increased visceral
adiposity was reflected in increased waist circumference
in both males and female SAIs (Table 2). This factor has
a direct relationship to an increased risk of CAD [12].
Accordingly, and correctly so, the description of BMI is
corrected for the SAIs race [16]. Thus obesity, by its
classic definition, is not a metabolic risk factor in the
S A I s .I nd e f i n i n gM Su n i q u et ot h eS A I s ,i ti si m p o r t a n t
to recognize the accelerated progression of coronary
atherosclerosis, leading to CAD at a younger age [3]. The
distinct features of MS with accelerated atherosclerosis in
the SAIs include visceral adiposity, insulin resistance/
hyperinsulinaemia, high LP(a) levels, low HDL levels, and
abnormal Apo A-I levels (Table 4). Although prevalence
of MS and dyslipidemia is determined by interplay
between environment and genetic factors, family and
twin studies have demonstrated a strong genetic herit-
ability, accounting for up to 66% of the variability in
HDL and Apo A-I levels [8]. Several studies in Caucasian,
SAIs, and other ethnic groups have shown that specific
lipoprotein polymorphisms do play a role and are consid-
ered predictors of MS [31-34]. APOA1 gene polymorph-
isms have been implicated to explain the variability in
HDL levels as well as to its dysfunction [31-35].
Table 4 Association of CAD risk factors with MS (n = 129)
MS P-Value**
Variable No Yes
Age (years) < 40 9 (8.0)+ 6 (5.3) 0.128
≥ 40 76 (67.3) 22 (19.5)
Gender Male 48 (42.5) 18 (15.9) 0.308
Female 37 (32.7) 10 (8.8)
Physical Activity No 12 (10.6) 3 (2.7) 0.461
Yes 73 (64.6) 25 (22.1)
Smoke No 81 (71.7) 25 (22.1) 0.234
Yes 4 (3.5) 3 (2.7)
Type 2 Diabetes
# No 66 (58.4) 21 (18.6) 0.479
Yes 19 (16.8) 6 (6.2)
Family history of T2D
$ No 37 (38.9) 8 (8.4) 0.313
Yes 38 (40.0) 12 (12.6)
Family history of CAD
$ No 44 (46.3) 12 (12.6) 0.326
Yes 31 (32.6) 8 (8.4)
Body Mass Index (kg/m^2) ≤23 22 (20.0) 3 (2.7) 0.005
23 - 30 48 (43.6) 18 (16.4)
≥30 12 (10.9) 7 (6.4)
Total LDL Normal (< 150 mg/dl) 69 (61.6) 22 (19.6) 0.433
Abnormal (≥ 150 mg/dl) 15 (13.4) 6 (5.4)
Total Cholesterol Normal (< 200 mg/dl) 49 (43.8) 16 (14.3) 0.542
Abnormal (≥ 200 mg/dl) 35 (31.3) 12 (10.7)
Apo lipoprotein A-1 Normal (94 - 176 mg/dl) 59 (52.7) 26 (23.2) 0.011
Abnormal 25 (22.3) 2 (1.8)
Lipoprotein [a] Normal (< 10 mg/dl) 48 (43.6) 26 (23.6) < 0.0001
Abnormal (≥10 mg/dl) 34 (30.9) 2 (1.8)
hsCRP* Normal (< 5 mg/L) 45 (40.9) 18 (16.4) 0.118
Abnormal (≥ 5 mg/L) 39 (35.5) 8 (7.3)
Homocysteine Normal (< 12 umol/L) 44 (53.7) 20 (24.4) 0.512
Abnormal (≥ 12 umol/L) 13 (15.9) 5 (6.1)
+n (%); *hsCRP = high sensitivity C reactive protein;
#History/examination and/or blood test;
$T2D = type II diabetes;
$CAD = Coronary Artery Disease; **Fisher’s Exact test.
Dodani et al. Lipids in Health and Disease 2011, 10:45
http://www.lipidworld.com/content/10/1/45
Page 6 of 10Furthermore, our findings involving novel SNPs in
APOA1 gene in SAIs [19] open avenues for further study
of SNPs in a larger sample and in relation to other con-
ventional and non-conventional CAD risk factors, includ-
ing MS.
The INTERHEART study reported a gradual increase
in the incidence of traditional risk factors for CAD in
the Indian Subcontinent [3]. Though this observational
study failed to establish a causative effect, this develop-
ment coupled with current study findings, in general
and genetic polymorphisms related to MS (considered
as an intermediate outcome for CAD) in particular, can
create an explosive situation in the SAI communities,
posing the threat of an unbridled and unprecedented
spread of CAD. This underlines the urgent need to act
quickly.
Similarly, in this cross sectional study of SAIs, we
found a significant relationship for MS with abnormal
ApoA-I levels, Lp [a] and importantly three of six SNPs
of the APOA1gene. These results support our hypoth-
esis of a possible pivotal role for APOA1 gene variation
predicting higher prevalence of MS and possibly CAD.
All six SNPs that were analyzed are intronic or located
in the non-coding region of the APOA1 gene. The
intron was historically thought to be a non-essential
region of DNA; however, with advancement in molecu-
lar biology, intronic regions are now known to play a
role in the regulation of transcription and translational
processes or in linkage disequilibrium with other causal
mutations.
The ApoA-I protein is essential for maintaining the
antioxidant and RCT (reverse cholesterol transport)
function of HDL. Decreased HDL is a well known risk
factor and predictor for CAD [2-6]. The growing body
of research looking into the qualitative assays of HDL,
etiology of Dys-HDL and its role in the pathogenesis
of atherosclerosis will eventually explain the high CAD
risk in a patient with normal HDL. Dys-HDL is not
only ineffective as an antioxidant but, paradoxically,
appears to be pro-oxidant by promoting LDL oxidation
and monocyte chemo-tactic activity in the human
artery wall as well as increasing HDL lipid hydroperox-
ides, as assessed by its lipid peroxide content [33]. This
pro-inflammatory dysfunctional HDL accumulates
Figure 1 Odds Ratio and 95% Confidence Interval for MS with CAD’s risk factors and Apo A-1 SNPs * T2D = type 2 diabetes; CAD =
Coronary Artery Disease; FT2D = Family History of T2D; FCAD = Family History of CAD;BMI = Body Mass Index; CCA-IMT = Common
carotid artery intimae media thickness; HII = HDL Inflammatory index measured by using cell-free assay; hsCRP = high sensitivity C
Reactive Protein; ^History/examination and/or blood test.
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enzymes, myeloperoxidases. This results in Apo A-I
oxidation that eventually blocks the function of ApoA-
1 and promotes cholesterol efflux, consequently pro-
moting the formation of LDL derived oxidized lipids
[34,35]. The mechanisms underlying this phenomenon
are not completely understood but it is thought that
Apo A-I variants are susceptible to oxidation and
nitration [34]. The presence of Dys-HDL may sub-
stantiate the CAD risk in MS patients at the onset of
T2D; however, additional studies are needed to provide
more supportive data.
Several limitations of this study must be considered.
First, this was a cross-sectional pilot study and, as in all
such studies, the data are exploratory; they do not allow
the establishment of causality and do not account for
changes over time. Second, we recruited participants
from local
Hindu temples, and therefore participants may not
be completely representative of the South Asian com-
munity. However, people attending these temples were
from mixed ethnic backgrounds, and data were col-
lected from participants who attended weekend wor-
ship services, which in general are attended by South
Asians from different and diverse ethnic groups.
Therefore, we anticipate that the selection bias is mini-
mal and the sample is representative of SAIs living in
t h eU S .O nt h es a m et o k e n ,w ea l s ou n d e r s t a n dt h e
heterogeneity among South Asians, and more research
is warranted in each ethnic group. Though these eth-
nic groups are from South Asians, among them preva-
lence of MS and its determinants may differ Third, we
did not assess diet in this study and is an area of
further work in future studies. Last, we were not able
to undertake further testing, and since this was a small
sample size, we were not able to make definitive con-
clusions regarding the association of dysfunctional
HDL with CAD and its risk factors. A larger longitudi-
nal study has been proposed.
Conclusion
Several studies have shown that SAIs have a higher
prevalence of CAD and MS (as per IDF criteria) com-
pared to other ethnic groups. In fact, evidence has
shown that MS is twice as prevalent in SAIs living in
the US compared to native Caucasians (30% versus
1 3 % )[ 8 ] .O u rs t u d ys h o w e dt h a tt h r e eo ft h es i xn o v e l
APOA1 SNPs were significantly associated with MS,
substantiating the CAD risk for APOA1 gene variants
in SAIs. Though larger cohort studies are required to
establish the etiologic role of SNPs in MS as well as of
Dys-HDL, their identification can be obtained at an
earlier age and aggressive measures, especially targeting
HDL therapies may prevent the future risk of CAD
and clustering of risk factors [36]. Treating Dys-HDL
with statins and niacin therapy, particularly in SAIs is
important to reduce the excess CAD risk in this high
risk group. We propose that the screening of Dys-HDL
in addition to conventional risk factors in high risk
groups is a potential target for prevention of cardiovas-
cular disease.
Table 5 APOA1 SNPs Association with Metabolic
Syndrome (n = 94)
APOA1 Gene Polymorphisms Metabolic Syndrome
Absent Present
G1 P319(T319C) WT 36 (42.5%) 13 (15.3%)
Heterozygous 25 (29.4%) 4 (4.7%)
Mutant 3 (3.5%) 4 (4.7%)
P-value
$ 0.940
G2 P655(T655C) WT 12 (14.1%) 0 (0.0%)
Heterozygous 22 (25.9%) 7 (8.2%)
Mutant 29 (34.1%) 15 (17.7%)
P-value 0.040
G3 P756(T756C) WT 12 (14.0%) 0 (0.0%)
Heterozygous 21 (24.4%) 7 (8.1%)
Mutant 30 (34.9%) 16 (18.6%)
P-value 0.039
G4 P938(C938T) WT 51 (59.3%) 15 (17.4%)
Heterozygous 12 (14.0%) 7 (8.1%)
Mutant 0 (0.0%) 1 (1.2%)
P-value 0.109
G5 P1001(T1001C) WT 12 (13.5%) 0 (0.0%)
Heterozygous 27 (30.3%) 11 (12.4%)
Mutant 25 (28.1%) 15 (16.9%)
P-value 0.054
G6 P1149(C1149T) WT 59 (66.3%) 23 (25.8%)
Heterozygous 5 (5.6%) 2 (2.3%)
Mutant 0 (0.0%) 0 (0.0%)
P-value 0.976
APOA1 = Apo lipoprotein A 1 gene, WT = Wild Type;
$P-values from the
logistical regression analysis.
Table 6 Association of MS, Dys-HDL and CCA-IMT ((age
and gender adjusted) (n = 129)
Variable CCA-IMT P-Value
$
< 0.8 mm ≥0.8 mm
MS No 46 (55.42)
# 15 (18.07) 0.0348
Yes 11 (13.25) 11 (13.25)
€y€-HDL HDL index <1 48 (51.61) 16 (17.20) 0.0024
HDL index ≥1 12 (12.90) 17 (18.28)
CCA-IMT = Common carotid artery intima media thickness; MS = Metabolic
Syndrome, defined according to IDF Central obesity and two or more of
fasting glucose (≥100 mg/dl or T2D), obesity, HDL (≥40 mg/dl), Blood Pressure
(≥130/≥85 mmHg); and Triglycerides (≥150 mg/d); Dys-HDL = Dysfunctional
HDL measure by HDL Inflammatory index using cell free assay
$Fisher’s Exact Test.
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Abbreviations
Apo A-I: Apo lipoprotein A-I; APOA1= Apo lipoprotein A-I gene; BMI: Body
mass index; CAD: Coronary artery disease; CCA-IMT: Common Carotid Intima-
Media Thickness; Dys-HDL: Dysfunctional high density lipoprotein; FHS:
Framingham Heart Study; hsCRP: high sensitivity C-reactive protein; TGs:
Triglycerides; IDF: International Diabetes Federation; LCAT: Lecithin:
Cholesterol acyl transferase; LDL: Low density lipoprotein; Lp[a]: Lipoprotein
[a]; MS: Metabolic syndrome NCEP ATP III: National Cholesterol Educational
Program ATP III; NIH: National Institutes of Health; RCT: Reverse cholesterol
transport; SAIs: South Asian immigrants; T2D: Type II diabetes; WC: Waist
circumference; WHO: World Health Organization.
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